Benitec Biopharma (BNTC) Operating Leases (2019 - 2025)

Benitec Biopharma has reported Operating Leases for 7 years, with the latest figure at $519000.0 in Q4 2025.

• Quarterly Operating Leases rose 278.83% year-over-year to $519000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $519000.0 (up 278.83% YoY) and the FY2025 annual result came in at $495000.0, changed N/A from the prior year.
• Operating Leases rose to $519000.0 in Q4 2025 per BNTC's latest filing, from $403000.0 in the prior quarter.
• Over five years, Operating Leases peaked at $954000.0 in Q3 2021 and troughed at $54000.0 in Q1 2021.
• A 5-year average of $449157.9 and a median of $422000.0 in 2022 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2023: Operating Leases surged 1075.93% in 2022, then slumped 67.54% in 2023.
• Over 5 years, Operating Leases stood at $698000.0 in 2021, then slumped by 39.54% to $422000.0 in 2022, then slumped by 67.54% to $137000.0 in 2023, then changed by 0.0% to $137000.0 in 2024, then jumped by 278.83% to $519000.0 in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $519000.0, $403000.0, and $495000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.